Phase 3
Completed N=342
Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation
Vitamin D3 Deficiency
Source: ClinicalTrials.gov NCT01932788 ↗
Enrolled (actual)
342
Serious AEs
0.0%
Results posted
Nov 2018
Primary outcomePrimary: Number of Participants With Greater Than 100 Nmol/L 25(OH)D (Converted Vitamin D) — 110; 22 Participants
◆ Published Evidence
Established
36citations · ~18 / year
Vitamin D supplementation for women during pregnancy.
Summary
The purpose of this study is to give all mothers the best chance for a healthy pregnancy through vitamin D supplementation. We will study women of diverse racial/ethnic backgrounds who will receive either the current vitamin D standard of 400 IU/day (in the prenatal vitamin) or 4000 IU/day (dose found in previous pregnancy studies to achieve vitamin D sufficiency).
This research is sponsored by the W.K. Kellogg Foundation and the Medical University of South Carolina. The purpose of this study is to examine the effectiveness and infection-fighting properties of the body in relationship to vitamin D levels. This study is being done at the Medical University of South Carolina (MUSC) clinics, and will involve approximately 450 volunteers.
Linked Publications
-
Vitamin D supplementation for women during pregnancy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Greater Than 100 Nmol/L 25(OH)D (Converted Vitamin D) |
110; 22 | — |
Eligibility Criteria
Inclusion Criteria
- Any mother (18-45 years of age) who presents to her obstetrician or midwife at the Medical University of SC (MUSC), Charleston, SC obstetrical facilities within the first 14 weeks after her last menstrual period (LMP) with confirmation of a singleton pregnancy will be eligible for enrollment in the study. Mothers of diverse ethnic backgrounds (African-American, Asian, Caucasian and Hispanic) will be actively recruited.
Exclusion Criteria
- Mothers with pre-existing calcium, uncontrolled thyroid disease, parathyroid conditions, or who require chronic diuretic or cardiac medication therapy including calcium channel blockers will not be eligible for enrollment into the study. Mothers with pre-existing sickle cell disease (not trait only), sarcoidosis, Crohn's disease, or ulcerative colitis may not participate in the study. In addition, because of the potentially confounding effect of multiple fetuses, mothers with multiple gestations will not be eligible for participation in the study. A sub-group of approximately 100 subjects with known diabetes, hypertension, HIV, or morbid obesity (body mass index > 49) will participate in the study.
Data sourced from ClinicalTrials.gov (NCT01932788) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.